INDIA'S RANBAXY HAILS US COURT RULING ON VALCYTE PATENT
RBXLF | Quote | Chart | News | PowerRating -- Indian drug company Ranbaxy
Laboratories (BSE:500359) today welcomed a ruling by a US
district court that said the company's generic version of
anti-viral drug Valcyte did not infringe Swiss pharma firm
Roche's patent.
"We welcome the positive development," a Ranbaxy
spokesperson said.
According to reports, the District Court of New Jersey has
ruled that Ranbaxy's generic version did not infringe Roche's
patented crystalline valganciclovir, the active ingredient in
anti-viral drug Valcyte. The court, however, held Roche's
patent on the product as valid.
Ranbaxy had filed an Abbreviated New Drug Application (ANDA)
on amorphous form of valganciclovir with the US Food and Drug
Administration (FDA) in 2006. This was challenged by Roche
saying the amorphous form of valganciclovir would change to
crystalline form and, thus, will infringe the patent.
The Ranbaxy spokesperson declined to comment on the
company's marketing plans after the ruling of the court.
(PTI)lm
For full details on (RBXLF) RBXLF. (RBXLF) has Short Term PowerRatings at TradingMarkets. Details on (RBXLF) Short Term PowerRatings is available at This Link.
- Syntropharma signs marketing agreement with Ranbaxy Pharmaceuticals for generic transdermal product - 02/02/10
- Ranbaxy launches anti-fungal chemical in India - 01/11/10
- Ranbaxy in talks to acquire Bangalore vaccine co for Rs 50-cr - 01/08/10
- Ranbaxy Laboratories signs license agreement with Summit Pharmaceuticals for Lulifin (Luliconazole) - 01/07/10
- Ranbaxy to transfer stake in Chinese operations to Chembio Pharmacy - 01/07/10
- More News >>
